Anticoagulation and antiplatelet management in gastrointestinal endoscopy: A review of current evidence

Table 29 Endoscopic mucosal resection

Ref.	Year	Country	Study design	n	Polyp morphology	Procedure	Medication	Relative risk
Ono et al[113]	2019	Japan	Retrospective	1734	Size: Median size 8.5-9.5 ± 5 mm	EMR	Thienopyridines (ceased 3-5 d before)	Incidence of PPB 1.35%
So et al[50]	2019	South Korea	Retrospective	399	Size: Mean lesion size 34 mm	EMR (and ESD)	Thienopyridines either: (1) Ceased day of procedure; (2) 0-4 d before; (3) Ceased 5-7 d before; (4) Ceased 8-14 d before	Incidence of PBB 8.2%
Albéniz et al[114]	2020	Spain	Prospective	1034	Size: ≥ 20 mm (mean size 30.5 mm)	EMR	Thienopyridines (ceased 5 d before)	Study expressed risk of PPB on antiplatelet monotherapy as OR: 2.51, 95%CI: 0.99-6.34, P < 0.001 (either aspirin or thienopyridine monotherapy)

OR: Odds ratio; EMR: Endoscopic mucosal resection; PPB: Post-procedural bleeding.